- Home
- WU vs KLRA Comparison
WU vs KLRA Comparison
Compare WU & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WU | KLRA |
|---|---|---|
| Founded | 1851 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2006 | 2026 |
Fundamental Metrics
Financial Performance| Metric | WU | KLRA |
|---|---|---|
| Price | $7.33 | $16.54 |
| Analyst Decision | Hold | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 11.5M | 510.6K |
| Earning Date | 04-24-2026 | N/A |
| Dividend Yield | ★ 10.47% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $4,050,700,000.00 | N/A |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $4.73 | N/A |
| P/E Ratio | $16.21 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.27 | $16.39 |
| 52 Week High | $10.35 | $23.82 |
Technical Indicators
Market Signals| Indicator | WU | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 35.66 |
| Support Level | $6.91 | $16.39 |
| Resistance Level | $7.52 | $19.13 |
| Average True Range (ATR) | 0.21 | 1.01 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 75.40 | 8.44 |
Price Performance
Historical ComparisonAbout WU Western Union Company (The)
Western Union provides domestic and international money transfers through its global network of over 500,000 outside agents. The company handled almost 290 million transactions in 2025 and is the largest money transfer company in the world.
About KLRA Kailera Therapeutics Inc. Common Stock
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.